Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468267 | 1.00 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL5493959 | 0.91 | CTSK (0.59) | CTSK | |
| SCHEMBL5493965 | 0.91 | CTSK (0.59) | CTSK | |
| SCHEMBL384008 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL15797176 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL9102463 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL384990 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL9943895 | 0.88 | CTSK (0.48) | CTSKCTSS | |
| SCHEMBL27674114 | 0.84 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL9106760 | 0.83 | CTSK (0.47) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014091443-A1 | CATHEPSIN C INHIBITORS FOR TREATING CYSTIC FIBROSIS, NON-CYSTIC FIBROSIS BRONCHIECTASIS, AND ANCA-ASSOCIATED VASCULITIS | GLAXO GROUP LIMITED (GB) | 2014-06-19 | — | — | WO | disclosed |
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | AGT SCIENCE LIMITED (GB) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263873-A1 | Enantioselective Synthesis of y-amino-alpha beta-unsaturated carboxylic acid derivatives | BCAT1, BCAT2, AADAT | CTSK 3626/4885CTSS 3541/4885 |
| US-20070099950-A1 | Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain | PER2, CNR2, OPRD1 | CTSK 2839/4885CTSS 3899/4885 |
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSK 8/4885CTSS 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.